In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647 (Telithromycin) against Chlamydia pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 7, 2000, Pages 1846-1849

  Gustafsson, I ^a   Hjelm, E ^a   Cars, O ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HMR 3004; KETOLIDE; MACROLIDE; TELITHROMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CHLAMYDOPHILA PNEUMONIAE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG POTENCY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; STRAIN DIFFERENCE;

ANTI-BACTERIAL AGENTS; CELLS, CULTURED; CHLAMYDOPHILA PNEUMONIAE; HUMANS; KETOLIDES; KINETICS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL;

EID: 0033936568     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.7.1846-1849.2000     Document Type: Article

References (20)

1. Barry, A. L., P. C. Fuchs, and S. D. Brown. 1998. In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae. Antimicrob. Agents Chemother. 42:2138-2140.
2. Boswell, F. J., J. M. Andrews, and R. Wise. 1948. Pharmacodynamic properties of HMR 3647, a new ketolide, on respiratory pathogens. enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect. J. Antimicrob. Chemother. 41:149-153.
3. Bryskier, A., C. Agouridas, and J. F. Chantot. 1997. Ketolides: new semisynthetic 14-membered ring macrolide, p. 39-50. In S. H. Zinner, L. S. Young, J. F. Acar, and H. C. Neu (ed.), Expanding indications for the new macrolides, azalides and streptogramins. Marcel Dekker Inc., New York, N.Y.
4. Campbell, L. A., E. R. O'Brien, A. L. Cappuccio, C. Kuo, S. Wang, D. Stewart, D. L. Patton, P. K. Cummings, and J. T. Grayston. 1945. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J. Infect. Dis. 172:585-588.
5. Carbon, C. 1998. Pharmacodynamics of macrolides, azalides and streptogramins: effect on extracellular pathogens. Clin. Infect. Dis. 27:28-32.
6. Falck, G., J. Gnarpe, and H. Gnarpe. 1996. Persistent Chlamydia pneumoniae infection in a Swedish family. Scand. J. Infect. Dis. 28:271-273.
7. Falck, G., I. Engstrand, A. Gad, J. Gnarpe, H. Gnarpe, and A. Laurila. 1997. Demonstration of Chlamydia pneumoniae in patients with chronic pharyngitis. Scand. J. Infect. Dis. 29:585-589.
8. Gnarpe, J., K. Eriksson, and H. Gnarpe. 1996. In vitro activities of azithromycin and doxycyclin against 15 isolates of Chlamydia pneumoniae. Antimicrob. Agents Chemother. 40:1843-1845.
9. Hahn, D. L., R. W. Dodge, and R. Golubjatnikov. 1991. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis and adult-onset asthma. JAMA 226:225-230.
10. Hansen, L. H., P. Mauvais, and S. Douthwaite. 1999. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol. Microbiol. 31:623-631.
11. Hultén, K., R. Rigo, I. Gustafsson, and L. Engstrand. 1996. New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. Antimicrob. Agents Chemother. 40:2727-2731.
12. Nyström-Rosander, C., S. Thelin, E. Hjelm, O. Lindquist, C. Påhlsson, and G. Friman. 1997. High incidence of Chlamydia pneumoniae in sclerotic heart valves of patients undergoing aortic valve replacement. Scand. J. Infect. Dis. 29:361-365.
13. Nyström-Rosander, C., K. Hultén, I. Gustafsson, O. Cars, L. Engstrand, and E. Hjelm. 1997. Susceptibility of Chlamydia pneumoniae to azithromycin and doxycyclin: methodological aspects on the determination of minimal inhibitory and minimal bactericidal concentrations. Scand. J. Infect. Dis. 29:513-516.
14. Odenholt-Tornqvist I, Löwdin E and Cars O. 1995. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin and azithromycin on respiratory tract pathogens. Antimicrob. Agents Chemother. 39: 221-226.
15. Reinert, R. R., A. Bryskier, and R. Lütticken. 1998. In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany. Antimicrob. Agents Chemother. 42:1509-1511.
16. Roblin, P. M., and R. Hammerschlag. 1998. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 42:1515-1516.
17. Saikku, P., M. Leinonen, K. Mattila, M. R. Ekman, M. S. Nieminen, P. H. Mäkelä, J. K. Huttunen, and V. Valtonen. 1988. Serological evidence of an association of a novel Chlamydia. TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet ii:983-986.
18. Schulin, T., C. B. Wennersten, M. J. Ferraro, R. C. Moellering, Jr., and G. M. Eliopoulos. 1998. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob. Agents Chemother. 42:1520-1523.
19. Vazifeh, D., H. Abdelghaffar, and M. T. Labro. 1997. Cellular accumulation of the ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin. Antimicrob. Agents Chemother. 41:2099-2107.
20. Vazifeh, D., A. Preira, A. Bryskier, and T. Labro. 1998. Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils. Antimicrob. Agents Chemother. 42:1944-1951.